PharmaVentures advises Lausanne Hospital (CHUV) and EPFL on their collaboration and founding of Aerium Therapeutics to develop their highly potent SARS-CoV-2 antibodies
PharmaVentures acts as transaction advisor to Lausanne University Hospital (CHUV) and EPFL.
London, UK, 24 March, 2022
PharmaVentures is pleased to announce that it acted as transaction advisor to Lausanne University Hospital (CHUV) and EPFL in Switzerland on their commercial terms related to the collaboration and licensing of their highly potent SARS-CoV-2 monoclonal antibodies to the newly founded biopharmaceutical company Aerium Therapeutics, based in Boston, MA, USA and Lausanne, Switzerland.
Fintan Walton, Founder and CEO of PharmaVentures, said “We are delighted to have advised CHUV and EPFL on their commercial terms for this break-through research that has significant potential to protect those who are left as most vulnerable to COVID-19.”
Dr. Giuseppe Pantaleo, Professor of Medicine at the CHUV, Head of Immunology and Allergy Division said “Our collaboration with Aerium Therapeutics will be key in delivering these antibodies to the clinical stage, where they have the potential to play an important role in the control and the prevention of COVID-19, particularly in all those who are not protected by vaccination.”